MB
Therapeutic Areas
Shionogi Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Investigational Oral COVID-19 Antiviral | COVID-19 | Clinical |
| Fragile X Program | Fragile X Syndrome | Clinical |
| Acute Stroke Program | Acute Ischemic Stroke | Clinical |
| Metabolic Disorders Program | Metabolic Conditions | Clinical |
| Oncology Program | Cancer | Clinical |
| Novel Antibiotics | Bacterial Infections | Various |
| HIV Therapeutics | HIV/AIDS | Approved |
| Influenza Treatments | Influenza | Approved |
Leadership Team at Shionogi
NM
Nathan McCutcheon
President and Chief Executive Officer
TH
Tadashi Hara
Executive Vice President and Chief Global Operations Officer
DB
David Benadon
Senior Vice President, Chief Human Resources Officer
MF
Masahiro Fujita
Senior Vice President and Chief Financial Officer
CK
Chris Klein
Senior Vice President and General Counsel